Latest Trastuzumab Stories
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
MADRID, April 14, 2015 /PRNewswire/ -- - Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic
RnRMarketResearch.com adds HER-2 Positive Breast Cancer Market in the US 2015-2019 and Global HER-2 Positive Breast Cancer Market 2015-2019 industry research reports in its store. DALLAS, March
WOONSOCKET, R.I., March 12, 2015 /PRNewswire/ -- MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc.
TAMPA, Fla., March 12, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc.
- Data highlights the use and potential of PEGPH20 to enhance the anti-cancer activity of monoclonal antibodies and NK cell access in breast and ovarian cancer preclinical models - SAN DIEGO,
SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
WORCESTER, Mass. and TORONTO, Oct.
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.